Claim 22	Page 6, line 27 – Page 7, line 9
Claim 23	Page 11, lines 24-28
Claim 24	Page 11, lines 24-28
Claim25	Page 19, line 11- Page 20, line 5

Consideration of the application as amended is respectfully requested.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By William D. Noonan
William D. Noonan, M.D.
Registration No. 30,878

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

Marked-up Version of Amended Claims and Specification
Pursuant to 37 C.F.R. §§ 1.121(b)-(c)

In the Specification:

At page one:

--PRIORITY CLAIM

This is a § 371 U.S. National Stage of PCT/US00/75666, filed June 8, 2000, which was published in English under PCT Article 21(2), which claims the benefit of U.S. Provisional Application 60/138,192, filed June 9, 1999.--

In the Claims:

22. (new) An antigen composition comprising synthetic cardiolipin, synthetic lecithin, cholesterol and ethanol, wherein the concentration of cardiolipin is between approximately 0.02 and 0.04%, the concentration of lecithin is between approximately 0.11 and 0.16%, and the concentration of cholesterol is approximately 0.9%.

23. (new) An antigen composition comprising between approximately 0.02 and 0.04% tetramyristoyl cardiolipin, between approximately 0.11 and 0.16% 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine, approximately 0.9% cholesterol, and ethanol to volume.

24. (new) An antigen composition comprising approximately 0.03% tetramyristoyl cardiolipin, between approximately 0.11 and 0.16% 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine, and approximately 0.9% natural cholesterol in absolute ethanol to volume.

25. (new) A method for detecting the presence of *Treponema pallidum* in a human comprising:

(a) obtaining a biological sample from a human;

(b) combining the biological sample with a composition comprising between approximately 0.02 and 0.04% tetramyristoyl cardiolipin, between approximately 0.11 and 0.16% 1-palmitoyl-2-oleoyl-*sn*-glycero-3-phosphocholine, approximately 0.9% cholesterol, and ethanol to volume; and

(c) detecting an immunocomplex formed between an antibody in the biological sample and the composition.